If BCG is successful and safe, I would welcome taking it every day
until the second agent is identified. We need a cure NOW. This is
an absolutely miserable disease to live with.

--- In nathanfaustmantrials@yahoogroups.com, "stilltypeone"
<stilltypeone@...> wrote:
>
> From Lynne Murphy at MGH:
>
> "Keep checking our website www.faustmanlab.org for updated
> information. We will also be informing all individuals in our
> database when the clinical trial is about to start. I think we are
> planning for early 2008."
>
> I believe this is for the BCG arm of the trial only. They have yet
> to identify the second agent, to make this "cure" permanent.
>
> Possibly another 10 to 15 years to identify the second agent?
>
>
> --- In nathanfaustmantrials@yahoogroups.com, "imcimc1"
> <curtieimc@> wrote:
> >
> >
> > Go the below website and lok on the right hand side
> under "Contact" and
> > it will give you information on who to contact about the trials.
> >
> > http://www.faustmanlab.org <http://www.faustmanlab.org>
> >
> >
> >
> >
> > --- In nathanfaustmantrials@yahoogroups.com, "mjspicer51"
> > <mjspicer51@> wrote:
> > >
> > > I am new to this group. I have been waiting for 20+ years to
see
> a
> > > cure or a real hope of a cure...What is happening seems to be
> faster
> > > than the ADA who seems satisfied with the band aid of using
> insulin
> > > instead of finding a real cure. How do I get my name on the list
> > > for the trials? I have two grandsons who I hope never have to
> deal
> > > with this desease personally. Thank you, would love to hear from
> > > anyone on this situation --- In
> > > nathanfaustmantrials@yahoogroups.com, "imcimc1" curtieimc@
> > > wrote:
> > > >
> > > > They have to automate the process. They cannot monitor even a
> > > small
> > > > group of people effectively day after day during the trial
> without
> > > > automation. I would rather see this automation process get off
> > > the
> > > > ground now instead of after phase 1 of the trial is finished.
> At
> > > > least the are working with some kind of vision and greater
> plan in
> > > > mind. My fingers are crossed with this one.
> > > >
> > > > --- In nathanfaustmantrials@yahoogroups.com, "stilltypeone"
> > > > <stilltypeone@> wrote:
> > > > >
> > > > > Sue, thanks for the info. I am still baffled that they
chose
> to
> > > > > spend time and money on the automation process, when it may
> be a
> > > > > moot point.
> > > > > If they can count T cells from hundreds of mice, can they
> not do
> > > > the
> > > > > same for such a small sample of humans?
> > > > >
> > > > >
> > > > > --- In nathanfaustmantrials@yahoogroups.com, Sue root
> > > > > <susan_root@> wrote:
> > > > > >
> > > > > > The procedure to separate and count the targeted T cells
> from
> > > > > whole blood samples in humans takes 1 ½ days by hand. Seeing
> > > that
> > > > > they plan to ultimately take blood samples every other day
> from
> > > the
> > > > > patients to monitor the effect, and they will plan to have
40
> > > > > patients in the trial with controls, the automation will
make
> > > this
> > > > > possible in a timely manner by decreasing the procedure to
> only
> > > > > about 6 hrs. More importantly, standardizing dosing in mice
> is
> > > much
> > > > > less of an issue compared to humans, even if we're talking
40
> > > people
> > > > > > Even though the NOD mouse is the best known animal model
> for
> > > type
> > > > > I diabetes, when dosing in mice, one doesn't have to deal
> with
> > > > > variables such as body weight. The groups of mice are born
at
> > > the
> > > > > same time, are the same size, and develop diabetes roughly
> the
> > > same
> > > > > time. Therefore, being able to standardize the dosing of
BCG
> in
> > > a
> > > > > group of humans with such variables, will be a key factor
for
> > > > > success.
> > > > > > What we do know is that the NOD mice have the same 2
> defects
> > > > > found in humans with type I diabetes and the treatment that
> Dr.
> > > > > Faustman used targets and eliminates these defects.
> > > > > >
> > > > > >
> > > > > > stilltypeone <stilltypeone@> wrote:
> > > > > > Patsy, I think you are misunderstanding what I am
> > > > > inferring.
> > > > > > The point I am making is why spend so much time and money
> on a
> > > > > > automation process that, in the end may end up as useless.
> > > Kind
> > > > of
> > > > > > like the "cart before the horse". Why not do the initial
> trial
> > > by
> > > > > > hand, as the mouse trials were done. If sucessful, then
> move
> > > on
> > > > to
> > > > > > scale this up to a larger group trial.
> > > > > > I would not expect death from BCG injections, as it is
> used in
> > > > > huge
> > > > > > quantities for bladder cancer.
> > > > > > The begining trial as I understand it will be 40
> individuals.
> > > I
> > > > > > consider that "small". I realize that is a relative term.
> > > > > > If asking questions is "grumbling" then I am guilty.
> > > > > >
> > > > > > --- In nathanfaustmantrials@yahoogroups.com, Patsy Van
> Huyck
> > > > > > <patsy@> wrote:
> > > > > > >
> > > > > > > The answer in short is because if a mouse dies, nobody
> > > cares.
> > > > > > Just
> > > > > > > think if the "small human trial" was a failure either
> due to
> > > > > huge
> > > > > > > complications or due to the lack of results. Do you
think
> > > that
> > > > > > they
> > > > > > > would just get to try again with another dose? The
assay
> is
> > > > very
> > > > > > > important so that the trial can be successful, and we
can
> > > then
> > > > > > move to
> > > > > > > the next stage.
> > > > > > >
> > > > > > > We all want the cure to have been in 2002, but dealing
> with
> > > the
> > > > > > FDA is
> > > > > > > tediously slow. Grumbling isn't going to get the
research
> > > done
> > > > > > any more
> > > > > > > quickly.
> > > > > > >
> > > > > > > Patsy
> > > > > > >
> > > > > > > >
> > > > > > > > Re: NEJM Correspondence
> > > > > > > >
> > > > > >
> > > > >
> > > >
> > >
>
<http://groups.yahoo.com/group/nathanfaustmantrials/message/245;_ylc=
> > > > > >
> > > > >
> > > >
> > >
>
X3oDMTJxMmg3MXB1BF9TAzk3MzU5NzE1BGdycElkAzE2NDEyMTQ1BGdycHNwSWQDMTcwN
> > > > > >
> > > > >
> > > >
> > >
>
TA2MTY2MgRtc2dJZAMyNDUEc2VjA2Rtc2cEc2xrA3Ztc2cEc3RpbWUDMTE3MDU4NDUyMQ
> > > > > > -->
> > > > > > > >
> > > > > > > >
> > > > > > > >
> > > > > > > > Posted by: "stilltypeone" stilltypeone@
> > > > > > > > <mailto:stilltypeone@?Subject=%20Re%3A%20NEJM%
> > > > > > 20Correspondence>
> > > > > > > > stilltypeone <http://profiles.yahoo.com/stilltypeone>
> > > > > > > >
> > > > > > > >
> > > > > > > > Sat Feb 3, 2007 6:57 pm (PST)
> > > > > > > >
> > > > > > > > Sue, can we agree that these trials will not proceed
> until
> > > > > > > > the "automated assay" is completed?
> > > > > > > > Did Faustman have this automated assay during the
mouse
> > > > trials?
> > > > > > > > I am guessing the answer is no.
> > > > > > > > So, why the need for automation for a small human
> trial?
> > > > > > >
> > > > > >
> > > > >
> > > >
> > >
> >
>